Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Moves To Allow More Private Health Care Insurance

This article was originally published in PharmAsia News

Executive Summary

India's health system is moving slowly in the direction of including more private industry in providing health insurance for the nation of more than 1.1 billion people. That trend is most evident in allowing private insurers to underwrite health plans that cover the disadvantaged, with the government paying part or all of the premiums. Various government ministries are testing other plans as the government moves into allowing private insurance coverage, eventually leaving much of the nation's health care to the private sector. But even the private sector is not expected to be able to do much to improve the nation's record on health spending, now among the world's lowest at 1.1 percent of gross domestic product. (Click here for more

You may also be interested in...



Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot

The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.

BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A

Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.

BridgeBio’s Hub-And-Spoke Model: An Interview With Cameron Turtle

Since raising $135m in 2017 to address rare, monogenic diseases, BridgeBio has launched or purchased 17 companies and built a pipeline of 30-plus candidates. Scrip checked in as the company nears commercialization.

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel